Lynotril5 mg

Lynotril is a synthetic progestin (a norethisterone-type prodrug) used in several markets, including Bangladesh, for the following indications:

• Progestin-only contraception: An established use where Lynotril-containing products are marketed as a progestin-only ("mini") pill for women who need or prefer a non-estrogen contraceptive method.
• Endometriosis: A guideline-supported, label-based use to suppress endometrial tissue growth and relieve associated pelvic pain, typically as a continuous course over several months.
• Menstrual cycle disorders: Used for management of dysfunctional (abnormal) uterine bleeding, menorrhagia (heavy periods), and dysmenorrhea (painful periods) once organic pathology has been excluded.
• Premenstrual syndrome and cyclical mastalgia: An adjunct, label-supported use in some markets for cyclical breast pain and premenstrual symptoms.
• Temporary postponement of menstruation: A short-term, on-label use to delay an expected period for a specific event, when medically appropriate.

Lynotril is not approved by the US FDA and does not appear in FDA/DailyMed labeling; the indications above reflect labeling and clinical use in the countries where it is marketed, including Bangladesh. A physician should confirm suitability for the specific indication before use.

Each tablet contains Lynestrenol as the active pharmaceutical ingredient, together with standard pharmaceutical excipients (such as lactose, maize starch, and magnesium stearate) used for tablet formulation. Strength varies by brand and intended use (commonly 0.5 mg tablets for contraceptive use and 5 mg tablets for endometriosis/menstrual disorder use) — always check the specific product label and consult a pharmacist for the exact composition of the brand dispensed.

Lynotril is a synthetic progestogen belonging to the 19-nortestosterone (estrane) class of steroids. It is a prodrug that is rapidly and almost completely converted in the body to norethisterone (norethindrone), the pharmacologically active moiety responsible for its progestational effects.

Lynotril is used clinically as a progestin-only oral contraceptive and, at higher doses, for the management of endometriosis and various menstrual cycle disorders. It does not contain an estrogen component.

Progestin (progestogen); 19-nortestosterone derivative and norethisterone prodrug — Lynotril is classified as a progestin-only hormonal agent used for contraception and menstrual disorder management.

Mechanism

Lynestrenol is rapidly metabolized after oral absorption, chiefly to norethisterone, which binds to progesterone receptors in the endometrium, hypothalamus, and pituitary gland.

• Contraceptive effect: thickens cervical mucus to impede sperm penetration, produces an endometrium unfavorable to implantation, and at higher doses can suppress ovulation by inhibiting the mid-cycle luteinizing hormone (LH) surge.
• Endometriosis/menstrual disorder effect: induces decidualization and eventual atrophy of endometrial and ectopic endometrial tissue, reducing menstrual blood loss and endometriosis-associated pain.

Pharmacokinetics

Lynestrenol is well absorbed orally, undergoes first-pass hepatic conversion to norethisterone, and its metabolites are excreted mainly in urine, with a minor fecal route. It is highly protein-bound in the circulation (mainly to albumin and sex hormone-binding globulin).

Take Lynotril by mouth, swallowed whole with water, at approximately the same time each day to maintain consistent hormone levels. It may be taken with or without food. Do not stop or skip doses without consulting a physician, particularly when using Lynotril for contraception, since timing affects contraceptive reliability.

• Hepatic enzyme-inducing drugs: Rifampicin, rifabutin, certain anticonvulsants (phenytoin, carbamazepine, phenobarbital, oxcarbazepine, topiramate), and St. John's Wort can increase the hepatic metabolism of Lynotril, reducing its contraceptive and therapeutic effectiveness; an additional non-hormonal contraceptive method is advised during and after use of such agents.
• HIV protease inhibitors and certain non-nucleoside reverse transcriptase inhibitors: May alter progestin metabolism and reduce contraceptive reliability; alternative or additional contraception should be considered.
• Ciclosporin: Progestins can inhibit the metabolism of ciclosporin, potentially increasing its plasma levels; monitoring is advised if co-administered.

Always inform the physician or pharmacist of all other medicines being taken before starting Lynotril.

Most side effects of Lynotril are mild and often improve after the first few months of use.

• Common: irregular menstrual bleeding or spotting, headache, nausea, breast tenderness, mood changes, weight fluctuation, and acne.
• Less common: decreased libido, fluid retention, dizziness, and skin changes (e.g., melasma).
• Rare but serious: venous thromboembolism, jaundice or liver dysfunction, and severe allergic reactions — seek prompt medical attention if these occur.

Pregnancy: Lynotril is contraindicated in known or suspected pregnancy (see Contraindications). If pregnancy occurs or is suspected during use, Lynotril should be discontinued and a physician consulted promptly.

Lactation: Small amounts of progestin metabolites pass into breast milk. Lynotril should be used during breastfeeding only if clearly needed and if the potential benefit justifies the potential risk to the infant; a physician should be consulted before use, and the infant should be monitored for any unusual effects.

• Use with caution in women with a history of, or risk factors for, venous thromboembolism, migraine, depression, or liver impairment; discuss individual risk factors with a physician before starting Lynotril.
• Irregular or breakthrough bleeding is common, especially in the initial months of use; persistent or heavy bleeding should be evaluated.
• Lynotril does not protect against sexually transmitted infections; barrier contraception is advised for STI protection.
• Missed or delayed doses can reduce contraceptive reliability; follow the specific missed-dose instructions provided with the product.
• Use caution in patients with diabetes, hypertension, or a history of jaundice during pregnancy, as periodic monitoring may be advised.

There is no specific antidote for Lynotril overdose. Reported effects of significant overdose may include nausea, vomiting, and withdrawal-type bleeding. If an overdose of Lynotril is suspected, seek immediate medical attention or contact a poison control center; treatment is supportive and symptomatic, and should only be provided by a healthcare professional.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Pediatric: Lynotril is not indicated for use before menarche (onset of menstruation); safety and efficacy in premenarchal or pediatric populations have not been established.
• Elderly: Lynotril is not indicated for use in postmenopausal women; it is intended for women of reproductive age.
• Hepatic impairment: Contraindicated in significant active liver disease (see Contraindications); use with caution and physician supervision in milder hepatic impairment.
• Renal impairment: No well-established dose adjustment is defined; use cautiously and under medical supervision.
• Obesity/smokers: Individual thromboembolic risk factors should be assessed by a physician before starting Lynotril.

Duration of Lynotril therapy depends on the indication: contraceptive use is typically continuous for as long as contraception is needed, subject to periodic medical review; endometriosis and menstrual disorder treatment courses commonly run for several months (often around 6 months) as directed by the physician; postponement of menstruation is a short-term course of only a few days. Do not continue or discontinue treatment without medical advice.

Lynestrenol belongs to the progestin (progestogen) class of hormonal agents, specifically the 19-nortestosterone (estrane) group, and functions as a norethisterone prodrug.

Lynestrenol is converted in the body mainly to norethisterone, which binds progesterone receptors to thicken cervical mucus, alter the endometrium, and (at higher doses) suppress the LH surge needed for ovulation, thereby producing contraceptive and endometrial-suppressive effects.

Lynotril is not indicated for use in children or premenarchal adolescents. Its use is restricted to women of reproductive age for contraception or menstrual/gynecological indications; safety and efficacy in pediatric populations have not been established, and it should not be used in this group.